Survival Outcomes Associated With the Size of Opioid Prescriptions in the Management of Chronic Pain Related to Advanced Nasopharyngeal Carcinoma.

IF 0.7 4区 医学 Q3 OTORHINOLARYNGOLOGY
Ent-Ear Nose & Throat Journal Pub Date : 2025-09-01 Epub Date: 2022-12-09 DOI:10.1177/01455613221145093
Kunhong Li, Shi Zhang, Wei Sun, Yaodong Zhang, Minji Yu, Guangwei Zhang, Weiguang Yu
{"title":"Survival Outcomes Associated With the Size of Opioid Prescriptions in the Management of Chronic Pain Related to Advanced Nasopharyngeal Carcinoma.","authors":"Kunhong Li, Shi Zhang, Wei Sun, Yaodong Zhang, Minji Yu, Guangwei Zhang, Weiguang Yu","doi":"10.1177/01455613221145093","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivePatients with advanced nasopharyngeal carcinoma (ANC) often experience chronic pain. Opioids are generally recommended to treat tumor-related pain, but increased opioid use may lead to detrimental aftereffects, particularly with respect to tumor progression, resulting in reduced quality of life and increased risk of death. Our objective was to investigate whether the high size of opioid prescriptions is associated with poor overall survival (OS) in patients with ANC.MethodsA consecutive cohort of patients with newly diagnosed ANC who underwent high or low opioid prescription size treatment during 2012-2019 was retrospectively identified from our medical institutions. Survival was estimated with the Kaplan-Meier method with a log-rank test. Multivariate binary logistic regression was used to assess the association between opioid use and OS, adjusting for age, sex, body mass index (BMI), Eastern Collaborative Oncology Group performance status (ECOG PS), and ANC histology. The criterion to distinguish between the high opioid prescription size group [HD] and the low opioid prescription size group [LD] was 5 mg of oral morphine equivalents (OME) per 24 hours.ResultsThe cohort consisted of 244 consecutive patients (HD: n = 120, median age = 66 years [range, 40-81 years]; LD: n = 124, median age = 65 years [40-82 years]. Patients who underwent treatment with a high opioid prescription size had a worse median OS than those who underwent treatment with a low opioid prescription size (5.1 vs 6.6 months), and the high opioid prescription size was associated with a remarkable 48% higher risk of death than the low opioid prescription size (HR 1.48, 95% CI 1.11-1.98; <i>P</i> = .005). The cumulative dose of opioids greater than or equal to 500 mg of OME was associated with a higher risk of death, adjusted for age, sex, BMI, ECOG PS, and ANC histology.ConclusionsIn patients with newly diagnosed ANC experiencing palliative care, a high opioid prescription size may be associated with shorter OS than a low opioid prescription size.</p>","PeriodicalId":51041,"journal":{"name":"Ent-Ear Nose & Throat Journal","volume":" ","pages":"NP631-NP637"},"PeriodicalIF":0.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ent-Ear Nose & Throat Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/01455613221145093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

ObjectivePatients with advanced nasopharyngeal carcinoma (ANC) often experience chronic pain. Opioids are generally recommended to treat tumor-related pain, but increased opioid use may lead to detrimental aftereffects, particularly with respect to tumor progression, resulting in reduced quality of life and increased risk of death. Our objective was to investigate whether the high size of opioid prescriptions is associated with poor overall survival (OS) in patients with ANC.MethodsA consecutive cohort of patients with newly diagnosed ANC who underwent high or low opioid prescription size treatment during 2012-2019 was retrospectively identified from our medical institutions. Survival was estimated with the Kaplan-Meier method with a log-rank test. Multivariate binary logistic regression was used to assess the association between opioid use and OS, adjusting for age, sex, body mass index (BMI), Eastern Collaborative Oncology Group performance status (ECOG PS), and ANC histology. The criterion to distinguish between the high opioid prescription size group [HD] and the low opioid prescription size group [LD] was 5 mg of oral morphine equivalents (OME) per 24 hours.ResultsThe cohort consisted of 244 consecutive patients (HD: n = 120, median age = 66 years [range, 40-81 years]; LD: n = 124, median age = 65 years [40-82 years]. Patients who underwent treatment with a high opioid prescription size had a worse median OS than those who underwent treatment with a low opioid prescription size (5.1 vs 6.6 months), and the high opioid prescription size was associated with a remarkable 48% higher risk of death than the low opioid prescription size (HR 1.48, 95% CI 1.11-1.98; P = .005). The cumulative dose of opioids greater than or equal to 500 mg of OME was associated with a higher risk of death, adjusted for age, sex, BMI, ECOG PS, and ANC histology.ConclusionsIn patients with newly diagnosed ANC experiencing palliative care, a high opioid prescription size may be associated with shorter OS than a low opioid prescription size.

治疗晚期鼻咽癌相关慢性疼痛的阿片类药物处方量与生存结果的关系
目的:晚期鼻咽癌(ANC)患者通常会经历慢性疼痛。一般建议使用阿片类药物治疗肿瘤相关疼痛,但阿片类药物用量增加可能会导致有害的后遗症,尤其是在肿瘤进展方面,从而导致生活质量下降和死亡风险增加。我们的目的是研究阿片类药物处方量大是否与ANC患者总生存率(OS)低有关:方法:从我们的医疗机构中回顾性地找到了2012-2019年期间接受阿片类药物处方量高或低治疗的新诊断ANC患者的连续队列。采用卡普兰-梅耶法和对数秩检验估算生存率。采用多变量二元逻辑回归评估阿片类药物使用与OS之间的关系,并对年龄、性别、体重指数(BMI)、东部肿瘤协作组表现状态(ECOG PS)和ANC组织学进行调整。高阿片类药物处方量组[HD]和低阿片类药物处方量组[LD]的区分标准是每24小时口服5毫克吗啡当量(OME):组群由 244 名连续患者组成(HD:n = 120,中位年龄 = 66 岁[40-81 岁];LD:n = 124,中位年龄 = 65 岁[40-82 岁])。接受阿片类药物处方量大的患者比接受阿片类药物处方量小的患者的中位OS更差(5.1个月 vs 6.6个月),阿片类药物处方量大的患者的死亡风险比阿片类药物处方量小的患者高48%(HR 1.48,95% CI 1.11-1.98;P = .005)。经年龄、性别、体重指数、ECOG PS和ANC组织学调整后,阿片类药物累积剂量大于或等于500毫克OME与更高的死亡风险相关:在接受姑息治疗的新诊断ANC患者中,阿片类药物处方量大可能比阿片类药物处方量小与较短的OS相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Ent-Ear Nose & Throat Journal
Ent-Ear Nose & Throat Journal 医学-耳鼻喉科学
CiteScore
3.20
自引率
0.00%
发文量
385
审稿时长
6-12 weeks
期刊介绍: Ear, Nose & Throat Journal provides practical, peer-reviewed original clinical articles, highlighting scientific research relevant to clinical care, and case reports that describe unusual entities or innovative approaches to treatment and case management. ENT Journal utilizes multiple channels to deliver authoritative and timely content that informs, engages, and shapes the industry now and into the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信